Form 4: PTC Therapeutics Executive Sells Shares

Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics, Inc., reported transactions involving the sale of common stock and the acquisition of stock options.

Summary

• Mark Elliott Boulding, Executive VP and Chief Legal Officer of PTC Therapeutics, Inc., engaged in several transactions on May 15, 2026.
• These transactions include the acquisition of 2,812 shares of common stock at a price of $25.69 per share, pursuant to a Rule 10b5-1 trading plan.
• Additionally, Mr. Boulding disposed of a total of 2,812 shares of common stock through sales executed at weighted average prices of $72.08 and $72.67 per share.
• Following these transactions, Mr. Boulding beneficially owns 105,668 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While an executive is selling shares, the transactions are conducted under a Rule 10b5-1 plan, which is a standard and compliant method for insider stock sales.

Positives

• Acquisition of 2,812 shares of common stock at a favorable price of $25.69, indicating potential confidence in future stock value or as part of a compensation package.
• The transactions were executed under a Rule 10b5-1 trading plan, suggesting a pre-determined and structured approach to stock transactions, which can mitigate insider trading concerns.

Negatives

• Sale of 2,812 shares of common stock, indicating a reduction in direct beneficial ownership by a key executive.
• The sale price of the disposed shares ($72.08 and $72.67) is significantly higher than the acquisition price ($25.69), suggesting a substantial profit was realized by the executive.

Risks

• Potential for negative market perception due to an executive selling shares, even if executed under a pre-planned trading strategy.
• The sale of shares could be interpreted by some investors as a lack of confidence in the company's immediate future prospects, despite the Rule 10b5-1 plan.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding the company's future financial performance. The transactions reported are related to executive stock ownership and are governed by a pre-established trading plan.

Management Comments

• The transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 10, 2025.
• The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price for the weighted average sales.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for executives and directors. The use of a Rule 10b5-1 plan by Mark Elliott Boulding is a common practice to diversify holdings or manage personal finances while adhering to insider trading regulations. The significant difference between the acquisition and sale prices of the common stock may reflect a substantial increase in PTC Therapeutics' stock value since the options were granted or the shares were acquired under the plan.

Stakeholder Impact

• Shareholders: The sale of shares by an executive might be perceived negatively, although the Rule 10b5-1 plan mitigates concerns about opportunistic trading. The acquisition of shares at a lower price could be seen as a positive signal if the executive believes in future appreciation.
• Employees: The executive's stock transactions may not have a direct impact, but could indirectly influence morale depending on the market's interpretation.
• Creditors: No direct impact is expected from this type of filing.

Next Steps

• The reporting person may be required to provide further details on specific sale prices upon request from the SEC, issuer, or security holders.
• Continued monitoring of executive stock transactions can provide insights into insider sentiment.

Key Dates

Keywords

PTC Therapeutics, PTCT, Form 4, Insider Trading, Stock Options, Common Stock, Beneficial Ownership, Rule 10b5-1, Executive VP, CLO, Securities Exchange Act